| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Oncternal Therapeutics, Inc. | 2,860,906 | 4.8% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Oncternal Therapeutics, Inc. | 1,005,532 | 2.0% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | Oncternal Therapeutics, Inc. | 3,197,538 | 6.5% | EDGAR |
| SC 13G/A | 2021-02-16 | ARMISTICE CAPITAL, LLC | Oncternal Therapeutics, Inc. | 1,280,930 | 3.0% | EDGAR |
| SC 13G/A | 2021-02-16 | CVI Investments, Inc. | Oncternal Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2020-12-18 | HYDE JOSEPH R III | Oncternal Therapeutics, Inc. | 1,468,142 | 3.0% | EDGAR |
| SC 13G | 2020-12-18 | CVI Investments, Inc. | Oncternal Therapeutics, Inc. | 2,500,000 | 6.4% | EDGAR |
| SC 13D/A | 2020-07-23 | Shanghai Pharmaceuticals (HK) Investment Ltd | Oncternal Therapeutics, Inc. | 1,573,975 | 7.7% | EDGAR |
| SC 13G | 2020-05-29 | ARMISTICE CAPITAL, LLC | Oncternal Therapeutics, Inc. | 1,576,471 | 9.1% | EDGAR |
| SC 13G/A | 2020-02-14 | PERCEPTIVE ADVISORS LLC | Oncternal Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2019-08-01 | HYDE JOSEPH R III | Oncternal Therapeutics, Inc. | 1,430,058 | 9.0% | EDGAR |
| SC 13D | 2019-06-17 | Shanghai Pharmaceutical (USA) Inc. | Oncternal Therapeutics, Inc. | 2,495,114 | 16.2% | EDGAR |
| SC 13G/A | 2019-02-14 | BIOTECHNOLOGY VALUE FUND L P | GTX INC /DE/ | 0 | 0.0% | EDGAR |
| SC 13G/A | 2019-02-14 | Boxer Capital, LLC | GTX INC /DE/ | - | 0.0% | EDGAR |
| SC 13G/A | 2019-02-14 | PERCEPTIVE ADVISORS LLC | GTX INC /DE/ | 1,443,333 | 6.0% | EDGAR |
| SC 13G | 2018-05-29 | PERCEPTIVE ADVISORS LLC | GTX INC /DE/ | 1,501,501 | 6.7% | EDGAR |
| SC 13G | 2018-02-20 | Boxer Capital, LLC | GTX INC /DE/ | 1,310,000 | 6.1% | EDGAR |
| SC 13G/A | 2018-02-14 | BIOTECHNOLOGY VALUE FUND L P | GTX INC /DE/ | 1,029,241 | 4.7% | EDGAR |
| SC 13G/A | 2018-01-03 | Formanek Investment Trust | GTX INC /DE/ | 824,387 | 3.8% | EDGAR |
| SC 13G | 2017-10-10 | Amzak Health Investors, LLC | GTX INC /DE/ | 1,356,697 | 6.2% | EDGAR |